Front-line immunosuppressive treatment of acquired aplastic anemia

Bone Marrow Transplantation

Volumn 48, Issue 2, 2013, Pages 174-177

  Dufour, C ^a   Svahn, J ^a   Bacigalupo, A ^b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

aplastic anemia; immunosuppression; treatment

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LYMPHOGLOBULINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACQUIRED APLASTIC ANEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; BLOOD CELL COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG RESPONSE; FEBRILE NEUTROPENIA; HEMATOPOIESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; REVIEW; SALVAGE THERAPY;

ANEMIA, APLASTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME;

EID: 84873459887     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.222     Document Type: Review

References (26)

1. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147: 43-70
2. Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A et al. Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplant Group. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: A report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007; 92: 11-18
3. Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 1999; 107: 330-334
4. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. Young, MD. N Engl J Med 2011; 365: 430-438
5. Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anemia Working Party. Blood 2012; 119: 5391-5396
6. Atta EA, Dias DS, Marra VL, e Azevedo AM. Comparison between horse and rabbit antithymocyte globulin as first line treatment for patients with severe aplastic anemia: A single centre retrospective study. Ann Hematol 2010; 89: 851-859
7. Halkes CJM, Brand A, von den Borne PA, Marijt EW, Willemze R, Veelken H et al. Increasing the dose of rabbit-ATG does not lead to a higher response rate in the first-line treatment of severe aplastic anaemia Annual Meeting of the European Group for Blood and Marrow Transplantation, Paris, 3-6 April 2011
8. Saracco P, Lorenzati A, Oneto R, Iori AP, Pillon M, Russo G et al. on behalf of the AIEOP Bone Marrow Failure Study Group. The Italian Registry of pediatric acquired aplastic anemia: A retrospective survey. Poster N1 1179. 371 Annual Meeting of the European Group for Blood and Marrow Transplantation, Paris, 3-6 April 2011
9. Vallejos C. on behalf of the Pethema-GETH (Spanish Bone Marrow Failure Study Group). Personal communication
10. Afable 2nd MG, Shaik M, Sugimoto Y, Elson P, Clemente M, Makishima H et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica 2011; 96: 1269-1275
11. Jeong DC, Chung NG, Lee JW, Jang PS, Cho B, Kim HK. Long term outcome of immunosupresive therapy with rabbit antithymocyte globulin (rATG) for childhood severe aplastic anemia for 15 years. 53rd ASH Annual Meeting: San Diego. Poster No. 1346
12. Saracco P, Quarello P, Iori AP, Zecca M, Longoni D, Svahn J et al. Cyclosporin A response and dependence in children with acquired aplastic anaemia: A multicentre retrospective study with long-term observation follow-up. Br J Haematol 2008; 140: 197-205
13. Sheinberg P, Nunez O, Sheinberg P, Weinstein B, Wu CO, Young NS. Cyclosporine taper does not prevent relapse in severe aplastic anemia. 53rd ASH Annual Meeting: San Diego. Poster No. 2406
14. Socie G, Mary JY, Schrezenmeier H, Marsh J, Bacigalupo A, Locasciulli A et al. Granulocyte-stimulating factor and severe aplastic anemia: A survey by the European Group for Blood and Marrow Transplantation. Blood 2007; 109: 2794-2796
15. Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporine A with or without G-CSF in adults: A multicenter randomized study in Japan. Blood 2007; 110: 1756-1761
16. Gluckman E, Rokicka-Milewka R, Hann I, Nikiforakis E, Tavakoli F, Cohen-Scali S et al. Results and follow-up of a phase III randomized study of recombinant human- granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 2002; 119: 1075-1082
17. Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Du?hrsen U et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: A study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 2011; 117: 4434-4441
18. Scheinberg P, Nunez O, Wu CO, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: Anti-thymocyte globulin, cyclosporine and mycophenolate mofetil. BrJ Haematol 2006; 133: 606-611
19. Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM et al. Treatment of severe aplastic anemia with a combination of horse anti-thymocyte globulin and cyclosporine, with or without sirolimus: A prospective randomized study. Haematologica 2009; 94: 348-354
20. Alsultan A, Goldenberg NA, Kaiser N, Graham DK, Hays T. Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children. Pediatr Blood Cancer 2009; 52: 626-630
21. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 2012; 119: 345-354
22. Sloand EM, Olnes MJ, Weinstein B, Wu C, Maciejewski J, Scheinberg P et al. Longterm follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab. Haematologica 2010; 95: 382-387
23. Risitano AM, Selleri C, Serio B, Torelli GF, Kulagin A, Maury S et al. Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT). Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: A pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010; 148: 791-796
24. Brodsky RA, Chen AR, Dorr D, Fuchs EJ, Huff CA, Luznik L et al. High-dose cyclophosphamide for severe aplastic anemia: Long-term follow-up. Blood 2010; 115: 2136-2141
25. Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B et al. Eltombopag and improved hematopiesis in refractory aplastic anemia. N Engl J Med 2012; 367: 11-19
26. Calado RT, Yewdell WT, Wilkerson KL, Regal JA, Kajigaya S, Stratakis CA et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 2009; 114: 2236-2243